Outcomes in the management of high-risk gestational trophoblastic neoplasia in trophoblastic disease centers in South America
Journal – International Journal of Gynecologic Cancer
Publication date – May – 2020
Authors – Izildinha Maestá, Marjory de Freitas Segalla Moreira, Jorge Rezende-Filho, Maria Inés Bianconi, Gustavo Jankilevich, Silvina Otero, Luz Angela Correa Ramirez, Sue Yazaki Sun, Kevin Elias, Neil Horowitz, Antonio Braga and Ross Berkowitz
Keywords – gestational trophoblastic disease; trophoblastic neoplasms
Open access – Yes
Speciality – Obstetrics and Gynaecology
World region South America
Country: Argentina, Brazil
Language – English
Submitted to the One Surgery Index on May 31, 2020 at 2:45 pm
Background: South America has a higher incidence of gestational trophoblastic disease than North America or Europe, but whether this impacts chemotherapy outcomes is unclear. The purpose of this study was to evaluate outcomes among women with high-risk gestational trophoblastic neoplasia (GTN) treated at trophoblastic disease centers in developing South American countries.
Methods: This retrospective cohort study included patients with high-risk GTN treated in three trophoblastic disease centers in South America (Botucatu and Rio de Janeiro, Brazil, and Buenos Aires, Argentina) from January 1990 to December 2014. Data evaluated included demographics, clinical presentation, FIGO stage, WHO prognostic risk score, and treatment-related information. The primary treatment outcome was complete sustained remission by 18 months following completion of therapy or death.
Results: Among 1264 patients with GTN, 191 (15.1%) patients had high-risk GTN and 147 were eligible for the study. Complete sustained remission was ultimately achieved in 87.1% of cases overall, including 68.4% of ultra high-risk GTN (score ≥12). Early death (within 4 weeks of initiating therapy) was significantly associated with ultra high-risk GTN, occurring in 13.8% of these patients (p=0.003). By Cox’s proportional hazards regression, factors most strongly related to death were non-molar antecedent pregnancy (RR 4.35, 95% CI 1.71 to 11.05), presence of liver, brain, or kidney metastases (RR 4.99, 95% CI 1.96 to 12.71), FIGO stage (RR 3.14, 95% CI 1.52 to 6.53), and an ultra-high-risk prognostic risk score (RR 7.86, 95% CI 2.99 to 20.71). Median follow-up after completion of chemotherapy was 4 years. Among patients followed to that timepoint, the probability of survival was 90% for patients with high-risk GTN (score 7-11) and 60% for patients with ultra-high-risk GTN (score ≥12).
Conclusion: Trophoblastic disease centers in developing South American countries have achieved high remission rates in high-risk GTN, but early deaths remain an important problem, particularly in ultra-high-risk GTN.
OSI Number – 20462
PMID – 32376739